10-Q: Tempus AI Reports Third Quarter 2024 Results, Highlights Revenue Growth and IPO Impact

Tempus AI's third quarter 2024 results show significant revenue growth driven by both genomics and data services, alongside the impact of its recent IPO.

Summary

• Tempus AI reported a net loss of $75.8 million for the third quarter of 2024, compared to a net loss of $53.4 million for the same period in 2023.
• Total net revenue for the quarter was $180.9 million, a 33% increase from $136.1 million in the third quarter of 2023.
• Genomics revenue increased by 20% to $116.4 million, while data and services revenue grew by 64% to $64.5 million.
• The company's operating expenses totaled $234.5 million, up from $180.8 million in the prior year's quarter.
• For the nine months ended September 30, 2024, the net loss was $692.8 million, compared to $163.6 million for the same period in 2023.
• The company completed its IPO on June 17, 2024, raising net proceeds of $382 million.
• The IPO resulted in the conversion of all outstanding redeemable convertible preferred stock into Class A and Class B common stock.
• Stock-based compensation expense was $509.4 million for the nine months ended September 30, 2024, primarily due to the IPO.
• The company's cash and cash equivalents totaled $388 million as of September 30, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth and successful IPO completion, the significant net losses and increasing operating expenses raise concerns. The company's future success will depend on its ability to manage costs and achieve profitability.

Positives

• Significant revenue growth in both genomics and data services segments.
• Successful completion of the IPO, providing substantial capital.
• Strong growth in data and services revenue, indicating increasing demand for the company's data products.
• Increased cash and cash equivalents position following the IPO.

Negatives

• Substantial net losses for both the quarter and the nine-month period.
• Significant increase in operating expenses, particularly in selling, general and administrative costs.
• Large stock-based compensation expense due to the IPO.
• Losses from equity method investments.

Risks

• The company's transition to profitability is dependent on achieving adequate revenue to support its cost structure.
• Future capital requirements will depend on the timing and extent of spending on research and development activities and growth-related expenditures.
• The company is subject to various legal matters and regulatory risks.
• The company's ability to secure reimbursement from payers and government health benefits programs is critical to its financial performance.
• The company's reliance on a limited number of suppliers for laboratory instruments and materials poses a risk.
• The company's international expansion exposes it to various business, regulatory, political, operational, financial, and economic risks.
• The company's collection, processing, use and disclosure of personally identifiable information is subject to privacy and security regulations.
• The company's use of AI in its products and services may result in operational challenges, legal liability, reputational concerns and competitive risks.
• The company's existing and any future debt may affect its flexibility in operating and developing its business and its ability to satisfy its obligations.

Future Outlook

The company believes its existing cash and cash equivalents and marketable equity securities at September 30, 2024 will be sufficient to fund its current operating plan through at least a period of one year from the date of issuance.

Management Comments

• The company strives to combine deep healthcare expertise with leading technology capabilities.
• The company endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare.
• The company aims to help physicians find the best therapies for their patients, help pharmaceutical and biotechnology companies make the best drugs possible, and enable patients to access emerging therapies and clinical trials when appropriate.

Industry Context

The announcement reflects the ongoing trend of integrating AI and machine learning into healthcare, particularly in diagnostics and drug development. The company's focus on combining genomic data with other multimodal datasets aligns with the industry's move towards personalized medicine.

Comparison to Industry Standards

• The company's revenue growth in both genomics and data services is strong compared to some of its competitors in the diagnostics and data analytics space, such as Foundation Medicine and Flatiron Health.
• However, the company's net losses are also significant, indicating a need to improve cost management and achieve profitability, which is a common challenge for many growth-stage companies in the healthcare technology sector.
• The company's reliance on a limited number of suppliers, such as Illumina, is a common risk in the industry, but the company's efforts to expand its laboratory capacity and diversify its supply chain will be important for long-term sustainability.
• The company's strategic collaborations with AstraZeneca and GlaxoSmithKline are similar to partnerships formed by other companies in the industry, but the company's ability to leverage these partnerships for revenue growth and product development will be key to its success.
• The company's investment in a joint venture with SoftBank is a unique approach to international expansion, which may provide a competitive advantage in the Japanese market.

Legal Proceedings

• The company received a subpoena from the Office of the Ohio Attorney General on May 19, 2022, regarding certain billing and patient records.
• The company received a Civil Investigative Demand from the U.S. Attorneys Office for the Eastern District of New York on March 4, 2024, related to compliance with the False Claims Act and the Anti-Kickback statute.
• Guardant filed a complaint against the company in the U.S. District Court for the District of Delaware on June 11, 2024, alleging patent infringement.

Related Party Transactions

• In 2018, the company received $1.5 million from a related party for assuming an office lease.
• The company has entered into various agreements with Pathos AI, Inc., encompassing access to the company's Lens product, sequencing, clinical research organization and other data services.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares in connection with the IPO and the acquisition of Ambry.
• Employees may benefit from stock-based compensation, but may also face uncertainty due to the company's financial performance.
• Customers may benefit from the company's expanding product offerings and services, but may also be affected by changes in pricing or reimbursement policies.
• Suppliers may benefit from increased business with the company, but may also face risks related to the company's financial performance.
• Creditors may be affected by the company's debt obligations and its ability to repay its debts.

Next Steps

• The company expects to utilize borrowings under the Additional Term Loan and the Revolving Credit Facility to fund the Cash Consideration for the Acquisition of Ambry and to pay fees and expenses related thereto.
• The company will continue to invest in new assay development and expansion into new disease areas.
• The company will continue to invest in technology personnel to support its Platform and new algorithm development.
• The company will continue to focus substantial resources on increasing adoption of, and coverage and reimbursement for, its current tests and any future tests it may develop.

Key Dates

Keywords

Genomics, Data Services, AI Applications, IPO, Revenue Growth, Net Loss, Stock-Based Compensation, Clinical Trials, Healthcare Technology, Precision Medicine